MLA
Kaufman, Howard L, et al. Durable Response Rate As an Endpoint In Cancer Immunotherapy: Insights From Oncolytic Virus Clinical Trials. BioMed Central, 2017. https://doi.org/10.17615/x0k6-s254
APA
Kaufman, H., Andtbacka, R., Collichio, F., Wolf, M., Zhao, Z., Shilkrut, M., Puzanov, I., & Ross, M. (2017). Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. BioMed Central. https://doi.org/10.17615/x0k6-s254
Chicago
Kaufman, Howard L, Robert H I Andtbacka, Frances A Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov et al. 2017. Durable Response Rate As an Endpoint In Cancer Immunotherapy: Insights From Oncolytic Virus Clinical Trials. BioMed Central. https://doi.org/10.17615/x0k6-s254